LLY

901.29

-0.96%↓

JNJ

235.03

-0.28%↓

ABBV

204.68

-0.16%↓

NVS

148.56

+0.66%↑

AZN

185.31

+0.58%↑

LLY

901.29

-0.96%↓

JNJ

235.03

-0.28%↓

ABBV

204.68

-0.16%↓

NVS

148.56

+0.66%↑

AZN

185.31

+0.58%↑

LLY

901.29

-0.96%↓

JNJ

235.03

-0.28%↓

ABBV

204.68

-0.16%↓

NVS

148.56

+0.66%↑

AZN

185.31

+0.58%↑

LLY

901.29

-0.96%↓

JNJ

235.03

-0.28%↓

ABBV

204.68

-0.16%↓

NVS

148.56

+0.66%↑

AZN

185.31

+0.58%↑

LLY

901.29

-0.96%↓

JNJ

235.03

-0.28%↓

ABBV

204.68

-0.16%↓

NVS

148.56

+0.66%↑

AZN

185.31

+0.58%↑

Home・Akcijų sąrašas・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

31.2 -2.32

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

30.45

Max

31.94

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-14M -81M
Pardavimai	75K 75K
Pelnas, tenkantis vienai akcijai	-1.22
Pelno marža	-108,422.667
Darbuotojai	198
EBITDA	-7.8M -81M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+69.53% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	501M 2.1B
Ankstesnė atidarymo kaina	33.52
Ankstesnė uždarymo kaina	31.2

Naujienos nuotaikos

By Acuity

100%

333 / 350 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

18.91 / 20.63 Palaikymas ir pasipriešinimas

Celldex Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-24 18:58; UTC

Pagrindinės rinkos jėgos

MDA Space Shares Drop After NASA Shifts Focus to Moon's Surface and Away From Space Station

2026-03-24 23:48; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-24 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

2026-03-24 23:33; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Rises, Boosted by Dollar Weakness -- Market Talk

2026-03-24 23:16; UTC

Rinkos pokalbiai

Venezuelan Opposition Leader Says Oil Output Could Reach 5 Million B/D -- Market Talk

2026-03-24 22:40; UTC

Uždarbis

Shanghai Fosun Pharmaceutical: Results Supported by Higher Rev From Innovative Drugs, Overseas Business >2196.HK

2026-03-24 22:40; UTC

Uždarbis

Shanghai Fosun Pharmaceutical 2025 Net CNY3.37B Vs. Net CNY2.77B >2196.HK

2026-03-24 22:40; UTC

Uždarbis

Shanghai Fosun Pharmaceutical 2025 Rev CNY41.50B Vs. CNY40.91B >2196.HK

2026-03-24 21:44; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-03-24 21:44; UTC

Rinkos pokalbiai

Sandfire's New Bull Excited by Kalkaroo Copper Deposit -- Market Talk

2026-03-24 20:59; UTC

Uždarbis

Medtronic PLC Cuts FY26 View To Adj EPS $5.50-Adj EPS $5.54 >MDT

2026-03-24 20:58; UTC

Svarbiausios naujienos

Israel Hits Russian-Iranian Weapons Smuggling Route in the Caspian Sea -- WSJ

2026-03-24 20:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Energy & Utilities Roundup: Market Talk

2026-03-24 20:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-03-24 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-03-24 20:25; UTC

Uždarbis

This Palantir-Linked Drone Stock Was Flying Under the Radar -- Until Now -- Barrons.com

2026-03-24 20:15; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Global Commodities Roundup: Market Talk

2026-03-24 20:10; UTC

Rinkos pokalbiai

Canada Mortgage Arrears Linked to Labor Market Performance -- Market Talk

2026-03-24 20:10; UTC

Uždarbis

Worthington Enterprises 3Q Sales $378.7M >WOR

2026-03-24 20:10; UTC

Uždarbis

Worthington Enterprises 3Q Adj EPS 98c >WOR

2026-03-24 20:10; UTC

Uždarbis

Worthington Enterprises 3Q EPS 92c >WOR

2026-03-24 19:25; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Canada Needs Roughly 100 Days to Meet IEA's Oil-Stock Release -- Market Talk

2026-03-24 19:06; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Futures Regain Ground As Strikes Continue in Middle East -- Market Talk

2026-03-24 18:51; UTC

Rinkos pokalbiai

Svarbiausios naujienos

U.S. Natural Gas Settles Higher As Oil Futures Gain -- Market Talk

2026-03-24 18:40; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Global Forex and Fixed Income Roundup: Market Talk

2026-03-24 18:40; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Mideast Conflict to Hobble But Not Derail Canadian Economy -- Market Talk

2026-03-24 18:34; UTC

Svarbiausios naujienos

Oil Production in the Middle East Will Take Months to Come Back, CEO says. Why $100 Oil Could Be Here to Stay. -- Barrons.com

2026-03-24 18:27; UTC

Rinkos pokalbiai

Inflation Pickup Could Keep Bank of Mexico on Hold -- Market Talk

2026-03-24 18:21; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Silver Snaps 9-Session Losing Streak -- Market Talk

2026-03-24 18:00; UTC

Įsigijimai, susijungimai, perėmimai

Gilead to Buy Ouro Medicines for $2.2 Billion. Why the Deal Is Key to Future Stock Gains. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Celldex Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

69.53% į viršų

12 mėnesių prognozė

Vidutinis 53.91 USD 69.53%

Aukščiausias 90 USD

Žemiausias 24 USD

Remiantis 12 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Celldex Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

12 ratings

Pirkti

Laikyti

Parduoti

Remiantis 12 analitikų, pateikusių Celldex Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

18.91 / 20.63Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.